Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
1058 Results for "
peripheral
" in MedChemExpress (MCE) Product Catalog:
Products (1058)
1058 Results for "peripheral" in MCE Product Catalog:
Cat. No.: HY-183620
PSB-24379 is a CD39 inhibitor that potently inhibits human membrane-bound CD39 (Ki = 77.4 nM) and truncated soluble human CD39 (Ki = 23.1 nM). PSB-24379 reduces the level of ATP hydrolysis in melanoma and breast cancer cell membranes. PSB-24379 partially reverses ATP-mediated suppression of T cell activation and proliferation in a high-ATP environment. PSB-24379 can be used in research related to melanoma and breast cancer .
Cat. No.: HY-183767
Target:
Aurora Kinase Anaplastic lymphoma kinase (ALK) Mitochondrial Metabolism Apoptosis Reactive Oxygen Species (ROS) Aldehyde Dehydrogenase (ALDH)
Research Areas:
Aurora kinase/ALK-IN-1 is a dual Aurora A kinase and ALK inhibitor with IC50 values of 0.296 μM and 0.332 μM, respectively. Aurora kinase/ALK-IN-1 induces G2/M cell cycle arrest, triggers mitochondrial apoptosis, elevates intracellular reactive oxygen species (ROS) levels, and inhibits ALDH1 activity. Aurora kinase/ALK-IN-1 demonstrates cytotoxicity and tumor selectivity. Aurora kinase/ALK-IN-1 can be used for the research of anaplastic large cell lymphoma .
Cat. No.: HY-P11868
Target:
Research Areas:
Cat. No.: HY-P992212
Target:
Research Areas:
Cat. No.: HY-P992390
Target:
Research Areas:
Cat. No.: HY-P992413
Target:
Research Areas:
Cat. No.: HY-P992440
Target:
Research Areas:
Cat. No.: HY-13443S
Synonyms: Exenatide (Leu-13C6,15N) TFA
Exendin-4 (Leu- 13C6, 15N) TFA (Exenatide (Leu- 13C6, 15N) TFA) is the 13C, 15N-labeled Exendin-4 (HY-13443). Exendin‑4 (Exenatide) is an orally active, blood-brain barrier-permeable glucagon-like peptide-1 receptor (GLP‑1 receptor) agonist that resists degradation mediated by dipeptidyl peptidase IV. Exendin‑4 mediates multiple glucose-regulating effects, including stimulation of glucose-dependent insulin secretion, inhibition of glucagon production, increase in β-cell mass, delay of gastric emptying, reduction of food intake, improvement of peripheral insulin sensitivity, and restoration of normal islet structure. Exendin‑4 inhibits oxidative stress, alleviates inflammatory responses, and reduces neuronal apoptosis. Exendin‑4 reduces the aggregation level of mutant huntingtin, improves motor function, prolongs survival time, and regulates the expression levels of leptin and ghrelin. Exendin‑4 can be used in research related to type 2 diabetes, acute ischemic stroke, and Huntington's disease .
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology
NYX-2925 is an orally active, blood-brain barrier-permeable NMDAR modulator, with EC50 values of 55 pM, 28 fM, 11 pM and 55 pM against NR2A, NR2B, NR2C and NR2D, respectively . NYX-2925 enhances synaptic plasticity, long-term potentiation, metaplasticity, structural plasticity, learning ability, memory capacity and circadian rhythm amplitude. NYX-2925 regulates the signaling pathways of Src kinase, EIF2, mTOR, CDK5 and protein kinase A (PKA). NYX-2925 increases the levels of PSD-95, GluA1, activated Src and synaptic GluN2B . NYX-2925 is used in the research of neuropathic pain, fibromyalgia, painful diabetic peripheral neuropathy, post-traumatic stress disorder, cognitive impairment, depression, age-related cognitive decline and NMDAR-mediated central nervous system diseases .
Cat. No.: HY-137055
CAS No.: 1171824-96-6
PF-3774076 is a highly central nervous system (CNS) penetrant, potent, and selective human α1A-adrenoceptor partial agonist. It exhibits good potency and selectivity in multiple binding and functional assays. PF-3774076 increases peak urethral pressure in anesthetized female dogs in a dose-dependent manner via a central mechanism. PF-3774076 affects both the proximal and distal portions of the urethra in vivo. These properties suggest that PF-3774076 may have significant benefit in the treatment of stress urinary incontinence (SUI) as a CNS-penetrant α1A receptor partial agonist. However, despite its partial agonism and selectivity for α1A receptors, PF-3774076 failed to provide adequate safety differences in in vivo models of cardiovascular function. This may be due to the simultaneous activation of both peripheral and central α1A receptors. These data suggest that while central α1A partial agonists may have significant benefit in the treatment of SUI, this class of agents may have difficulty achieving the desired urethral selectivity without affecting cardiovascular function.
Cat. No.: HY-145473S
Synonyms: 15(S)-HETE-SAPE; 15(S)-Hydroxyeicosatetraenoic acid-SAPE-d11; 1-Stearoyl-2-15(S)-HETE-sn-glycero-3-Phosphatidylethanolamine-d11
Cat. No.: HY-164401A
CAS No.: 1802735-31-4
Research Areas:
QBS10072S dihydrochloride is a LAT1-selective substrate with blood-brain barrier permeability that inhibits tumor growth. QBS10072S dihydrochloride enters LAT1-expressing tumor cells via LAT1-mediated active transport, induces interstrand DNA cross-linking and cell apoptosis, and reduces leptomeningeal dissemination. QBS10072S dihydrochloride can be used in studies related to glioblastoma multiforme, diffuse intrinsic pontine glioma, triple-negative breast cancer brain metastases, and aggressive T-cell lymphoma .
Cat. No.: HY-184508
Target:
Research Areas:
E3 ligase Ligand 81 is a VHL E3 ubiquitin ligase ligand and constitutes the VHL ligand moiety of R4VPL3-1 (HY-184506). R4VPL3-1 is a PROTAC-like bifunctional degrader linking RNF4 and VHL; it binds to and modifies GPX4, thereby inhibiting its anti-ferroptotic function. R4VPL3-1 induces iron-dependent lipid peroxidation and rapid ferroptosis-mediated cell death in cancer cells. E3 ligase Ligand 81 can be used in research related to targeted protein degradation and tumors such as melanoma .
Cat. No.: HY-186050
CAS No.: 3105300-99-7
Target:
Research Areas:
GIPR antagonist 2 is a glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist with an IC50 of 7.2 nM in CHO-K1 cells. GIPR antagonist 2 can be used in research related to diseases such as obesity, type 2 diabetes, non-alcoholic fatty liver disease, and atherosclerosis .
Cat. No.: HY-NP143
CAS No.: 93928-24-6
Cat. No.: HY-P991665
Synonyms: OBT357NF; OBT357
Target:
Research Areas:
Cat. No.: HY-P992052
Research Areas:
Cat. No.: HY-121272
CAS No.: 98106-17-3
Synonyms: A-56619
Target:
Research Areas:
Difloxacin (A-56619) is an orally active bactericidal agent. Difloxacin inhibits bacterial DNA gyrase. Difloxacin exhibits concentration-dependent bactericidal activity. Difloxacin shows strong in vitro activity against a variety of Gram-positive and Gram-negative bacteria. Difloxacin can be used in research related to colibacillosis and Staphylococcus aureus infections .
Cat. No.: HY-149906
CAS No.: 153021-75-1
Synonyms: GEM91
Trecovirsen (GEM91) is an antiviral agent targeting HIV gag mRNA, which hybridizes with complementary HIV gag mRNA at the initiation site. Trecovirsen induces a reversible, dose-dependent prolongation of activated partial thromboplastin time via its polyanionic property. Trecovirsen is applicable to research related to HIV infection .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
